Results 81 to 90 of about 453,541 (160)

Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial

Caspian Journal of Internal Medicine, 2021
Background: Pre-operative chemoradiotherapy (NACRT) of patients with proximal gastric and esophagogastric junction (EGJ) adenocarcinoma may result in increased local control and improved patients’ survival rate. This study aimed to investigate the effect
Seyed Amir Aledavood, Kazem Anvari, Soodabeh Shahidsales, Sare Hosseini, Ali Emadi Torghabeh, Masume Masudian   +5 more
doaj  

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, Volume 50, Issue 8, Page 2081-2084, August 2026.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Evaluating the Additional Value of Endoscopic Ultrasonography for Depth Assessment of Esophagogastric Junction Adenocarcinoma

DEN Open
Objectives Endoscopic ultrasonography (EUS) is sometimes used to assess the depth of invasion in esophagogastric junction adenocarcinoma (EGJA); however, its diagnostic performance in EGJA remains unclear.
Keita Suzuki, Yohei Ikenoyama, Ken Namikawa, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Manabu Takamatsu, Takahisa Matsuda, Junko Fujisaki   +11 more
doaj   +1 more source

Esophagopericardial fistula as a rare complication after total gastrectomy for cancer

World Journal of Surgical Oncology, 2009
Background Esophagopericardial fistula is a rare but life-threatening complication of benign, malignant or traumatic esophageal disease. It is most commonly associated with benign etiology and carries a high mortality rate which increases with delay in ...
Athanasopoulos Panayiotis, Fragulidis Georgios, Gkiokas Georgios, Polydorou Andreas, Marinis Athanasios, Anastasopoulos Georgios, Dafnios Nikolaos, Theodosopoulos Theodosios   +7 more
doaj   +1 more source

Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction

, 2010
Background \ud Adenocarcinoma of the esophagogastric junction (AEG) as described by Siewert et al. is classified as one entity in the latest (7th Edition) American Joint Cancer Committee/International Union Against Cancer (AJCC/UICC) manual, compared ...
Ravi, Naraymasamy, Larkin, John O., O'Byrne, Kenneth J., John V. Reynolds, Donal Hollywood, Muldoon, Cian, Rowley, Suzanne, Cian Muldoon, Ken O’Byrne, Dermot O’Toole, O'Toole, Dermot, Suzanne Rowley, Hollywood, Donal, Narayanasamy Ravi, Reynolds, John V., John O. Larkin   +15 more
core   +1 more source

Gastroesophageal reflux disease and esophagogastric junction adenocarcinoma [PDF]

, 2014
Представлены различные гипотезы этиологии развития рака пищеводно−желудочного соединения, его связь с гастроэзофагеальной рефлюксной болезнью.Подано різні гіпотези щодо етіології розвитку раку стравохідно−шлункового з'єднання, його зв'язку з ...
Васильев, Ю.В.
core   +1 more source

Chemotherapy for Esophageal Adenocarcinoma

, 2018
Esophageal and esophagogastric junction adenocarcinoma is a distinct entity from esophageal squamous cell carcinoma with respect to etiology and biology despite sharing the same anatomical location. While most international treatment guidelines recommend
Lam, KO, Dora L. W. Kwong, Ka-On Lam, Kwong, DLW   +3 more
core   +1 more source

Expression of MUC2 Glycoprotein Antibody and Vascular Endothelial Growth Factor in Barrett’s Mucosa

Acta Clinica Croatica, 2019
Higher expression of the mucin 2 (MUC2) glycoprotein and vascular endothelial growth factor (VEGF) in Barrett’s mucosa may be associated with a higher risk of esophageal adenocarcinoma development.
Melanija Ražov Radas
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study

Background: Optimal multimodal treatment for esophagogastric junction adenocarcinoma remains debated. While the ESOPEC trial supports perioperative FLOT, real-world evidence is limited, particularly for Siewert type II tumors.
Atci, Muhammed Mustafa, Mermit Ercek, Berrak, Erciyestepe, Mert, Gurdal, Necla, Akyel, Resit, Aydin, Okan, Ürün, Muslih, BİLİCİ, Mehmet, Gunenc, Senar, Celik, Emir, Erturk, Kayhan, Sucuoglu Isleyen, Zehra, Gurbuz, Halide Sena, Sakin, Abdullah, Dinc Sonusen, Sermin   +14 more
core   +1 more source